A novel hirudin derivative characterized with anti-platelet aggregations and thrombin inhibition
Research article published in Journal of thrombosis and thrombolysis (2008)
Abstract
BACKGROUND: Hirudin is an anti-coagulative product of the salivary glands of the medicinal leech Hirudo medicinalis. It is a powerful and specific thrombin inhibitor. Peptides containing the RGD motif competitively inhibit the binding of fibrinogen to GP IIb/IIIa on the platelets, thus inhibiting platelet aggregation. RESULTS: We have constructed a recombinant RGD-hirudin (r-RGD-hirudin) by fusing the tripeptide RGD sequence to the native hirudin (wt-hirudin). The r-RGD-hirudin was expressed at high levels in Pichia pastoris, and was purified to approximately 97% homogeneity. The specific anti-thrombin activity of purified r-RGD-hirudin is 12,000 ATU/mg, which is equivalent to wt-hirudin, but only r-RGD-hirudin can inhibit platelet aggregation. The biological effects of r-RGD-hirudin on Thrombin Time (TT), Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT), Bleeding Time (BT), maximum platelet aggregation (PAGm) induced by ADP were studied in rabbit model and compared with that of wt-hirudin. The rabbits were infused r-RGD-hirudin had prolonged TT, PT, and aPTT which were similar to that of wt-hirudin; but only r-RGD-hirudin was capable of inhibiting PAGm. Histopathological analyses showed that r-RGD-hirudin was two to three times more effective than wt-hirudin in preventing thrombosis. CONCLUSIONS: r-RGD-hirudin can potentially be used as a novel anti-coagulant for the prevention of thrombosis after carotid artery anastomosis or in other thrombotic events.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Hirudin is an anti-coagulative product of the salivary glands of the medicinal leech Hirudo medicinalis.
Warum dies für die Hirudotherapie relevant ist
Diese Studie konstruierte ein rekombinantes RGD-Hirudin durch Fusion eines RGD-Tripeptids an natives Hirudin aus Hirudo medicinalis, exprimierte es in Pichia pastoris und evaluierte seine dualen antikoagulatorischen und thrombozytenaggregationshemmenden Aktivitäten in Kaninchen. Das r-RGD-Hirudin behielt eine äquivalente Antithrombin-Aktivität (12.000 ATU/mg) wie Wildtyp-Hirudin bei und hemmte darüber hinaus einzigartig die ADP-induzierte Thrombozytenaggregation; in der histopathologischen Beurteilung war es zwei- bis dreimal wirksamer bei der Thromboseprävention. Dies ist relevant für den Zuständigkeitsbereich der ASH, da es ein verbessertes bifunktionales Derivat eines aus Blutegeln stammenden Antikoagulans entwickelt. Allerdings handelt es sich um eine präklinische Tierstudie ohne Beteiligung von Blutegeln oder Hirudotherapie; das Molekül ist ein rekombinantes Fusionskonstrukt und keine natürliche Komponente des Blutegelsekrets.
Zitation
A novel hirudin derivative characterized with anti-platelet aggregations and thrombin inhibition
Mo W et al. · Journal of thrombosis and thrombolysis, 2008
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026